Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.
March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” JAK inhibitors can help regrow hair in alopecia areata but have potential long-term risks and require careful monitoring.
JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
January 2025 in “BioMed Research International” Targeting DNA methylation can help treat skin disorders and cancers.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
July 2024 in “Journal of Investigative Dermatology” ATR04-484 ointment shows promise for treating skin issues from cancer therapies.
July 2024 in “International Journal of Molecular Sciences” The inhibitor DPP can promote hair growth.
June 2024 in “Military medicine” JAK inhibitors like baricitinib and ritlecitinib are effective new treatments for severe alopecia areata.
June 2024 in “Military Medicine” Access to JAK inhibitors for alopecia areata should be improved in the Military Healthcare System.
May 2024 in “Deleted Journal” Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.
May 2024 in “Current perspectives on medicinal and aromatic plants” Plant-based treatments might help with hair loss and have fewer side effects than synthetic drugs.
April 2024 in “Journal of translational medicine” MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
February 2024 in “Australasian journal of dermatology” Janus kinase inhibitors may help treat lichen planopilaris.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
Baricitinib may effectively treat oral lichen planus.
January 2024 in “Journal of Crohn's and colitis” Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
January 2024 in “Updates in clinical dermatology” JAK inhibitors, PRP, and exosomes show promise for hair regrowth in Alopecia Areata.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” OR-101 shows promise for treating alopecia areata by improving hair growth.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors partially restore scalp bacteria balance in alopecia areata patients.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Oral Janus kinase inhibitors may be an effective treatment option for lichen planopilaris with some risk of increased cholesterol and liver enzyme levels.
October 2023 in “Frontiers in medicine” Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
September 2023 in “Journal of the American Academy of Dermatology” Topical tofacitinib helped a man with severe scalp condition after other treatments failed.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.